Innovative Autoimmune Solutions SetPoint Medical's proprietary neurostimulation platform targeting chronic autoimmune diseases presents a significant opportunity to collaborate with healthcare providers and hospitals seeking advanced, minimally invasive therapies for rheumatoid arthritis and similar conditions.

Strong Funding & Backing With recent investments totaling over 115 million dollars including contributions from Boston Scientific and Abbott, the company is well-funded to expand commercialization efforts, enabling targeted sales strategies toward clinics and medical institutions adopting novel neuroimmune therapies.

Strategic Industry Engagement Participation in prominent industry events like ACR Convergence 2025 and the Piper Sandler Healthcare Conference indicates active engagement with key stakeholders and thought leaders, offering opportunities for direct outreach, partnerships, and clinical collaboration.

Market Expansion Potential Recent clinical data presentations and awards, coupled with FDA and regulatory pathway progress, position SetPoint Medical for potential market expansion into broader autoimmune and inflammatory conditions, increasing sales opportunities for neurological and immunology specialists.

Growing Clinical Evidence The company's engagement in ongoing clinical research and recognition at scientific congresses highlights its commitment to evidence-based validation, creating credible prospects for convincing healthcare providers and payers to adopt its innovative treatment platform.